Article
Genetics & Heredity
Qiwei Wang, Yinan Zhao, Fang Wang, Guolin Tan
Summary: This study identified the infiltration of cancer-associated fibroblasts (CAFs) as a hallmark signature of the tumor microenvironment in head and neck squamous cell carcinoma (HNSCC). By analyzing CAFs gene expression patterns and using machine learning algorithms, a stable and accurate risk model was developed to classify HNSCC patients.
FRONTIERS IN GENETICS
(2023)
Review
Cell Biology
Lesly J. Bueno-Urquiza, Marcela G. Martinez-Barajas, Carlos E. Villegas-Mercado, Jonathan R. Garcia-Bernal, Ana L. Pereira-Suarez, Maribel Aguilar-Medina, Mercedes Bermudez
Summary: Head and neck squamous cell carcinoma (HNSCC) is a group of cancers originating from the mucosal epithelium in various areas of the head and neck. Long non-coding RNAs (lncRNAs) play a key role in the diagnosis, prognosis, and treatment of HNSCC. However, there is limited research on the participation of lncRNAs in shaping the tumor microenvironment (TME) and their impact on immunotherapy efficacy.
Article
Oncology
Meng Zhang, Junlong Zhu, Pan Zhang, Lingxun Li, Min Min, Tinghao Li, Weiyang He
Summary: Bladder cancer is a common and highly morbid cancer of the genitourinary system. Cancer-associated fibroblasts (CAFs) play a critical role in the development of bladder cancer. In this study, we identified five genes associated with CAFs and constructed a prognostic model for bladder cancer.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemical Research Methods
Chengcheng Liao, Qian Wang, Jiaxing An, Hui Wang, Linlin Xiao, Qian Long, Hongbo Zhao, Jianguo Liu, Xiaoyan Guan
Summary: This study investigated the biological function and key pathways regulated by the FAM3 family in head and neck squamous cell carcinoma (HNSCC). It was found that high FAM3A expression promoted HNSCC mitochondrial biosynthesis and energy metabolism, inhibited immune cell infiltration, and was associated with poor prognosis. On the other hand, low expression levels of FAM3B were associated with poorer prognosis in HNSCC patients, possibly due to its ability to inhibit HNSCC development by increasing immune cell infiltration and inhibiting epithelial-mesenchymal transition. FAM3C overexpression was associated with increased oral squamous cell carcinoma (OSCC) cell stemness, immune escape, and EMT, as well as poor prognosis in HNSCC patients. FAM3D played a role in maintaining the epithelial phenotype and inhibiting EMT, promoting immune cell infiltration and inhibiting HNSCC progression. Methylation levels of the FAM3 gene family were also correlated with overall survival rate of HNSCC. Overall, the FAM3 family may serve as a biomarker and potential therapeutic target for HNSCC.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
(2023)
Article
Oncology
Guohong Liu, Chunjue Yuan, Jiaojiao Ma, Yunbao Pan, Haibo Xu
Summary: This study analyzed the immune cell types and tumor purity in HNSCC tissues, revealing their impact on tumor staging and survival prediction. The findings provide valuable insights for the diagnosis, prognosis, and immune therapy of HNSCC.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Pei Zhang, Shue Li, Tingting Zhang, Fengzhen Cui, Ji-Hua Shi, Faming Zhao, Xia Sheng
Summary: A study conducted on head and neck squamous cell carcinoma (HNSCC) identified three robust subtypes with distinct molecular characteristics, providing guidance for prognosis and treatment allocation. The research revealed molecular diversity in HNSCC tumors and established a new classification strategy based on genomic information from different subtypes.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Naifei Chen, Dongsheng He, Jiuwei Cui
Summary: This study investigates NET-related genes and their clinical prognostic value in Head and Neck Squamous Cell Carcinoma (HNSCC) patients. The study identifies a novel prognostic model that may aid in developing personalized treatments for HNSCC patients. Additionally, the study explores the relationship between these genes and immunotherapy and anticancer drugs.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Article
Multidisciplinary Sciences
Tingting Shu, Xudong Wang
Summary: In this study, the expression and clinical information of CRGs and TME cells in 502 HNSC patients were analyzed, and a Prognostic Cuproptosis and TME classifier were established. It was found that these classifiers were significantly associated with prognosis, pathways, clinical features, and immune cell infiltration in HNSC TME. GO enrichment analyses and single-cell analysis revealed the conjoint effect of Cuproptosis and TME on tumor angiogenesis and proliferation, and the prognostic risk score was positively correlated with T cell activation and natural killer (NK) recruiting. This study is the first to explore the involvement of CRGs regulation in the TME of HNSC, providing important references for the development of new therapeutic strategies.
Review
Medicine, General & Internal
Zhaomeng Guo, Kang Li, Peng Liu, Xiangmin Zhang, Jie Lv, Xianhai Zeng, Peng Zhang
Summary: Head and neck squamous cell carcinoma (HNSCC) originates from different parts of the head and neck, and the causes and molecular basis can vary. The tumor microenvironment (TME) consisting of various cells and molecules is crucial for the survival and spread of cancer cells. Understanding the interaction between tumor cells and the TME is essential for developing effective anti-cancer therapies.
FRONTIERS IN MEDICINE
(2023)
Article
Endocrinology & Metabolism
Yu Liu, Nana Liu, Xue Zhou, Lingqiong Zhao, Wei Wei, Jie Hu, Zhibin Luo
Summary: This study identified key genes related to glucose metabolism in HNSC and discovered five prognosis-related genes. A nomogram incorporating age, lymph node status, and risk score was constructed for survival prediction in HNSC patients, emphasizing the crucial role of GMRGs in HNSC.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Immunology
Ye Zhang, Pengbo Dong, Lu Yang
Summary: Head and neck squamous cell carcinomas (HNSCCs) are a group of highly malignant and pathogenically complex tumors. Traditional treatment methods include surgery, radiotherapy, and chemotherapy. However, nanotherapy has emerged as a more effective and safer alternative option for HNSCC patients, offering advantageous targeting capabilities, low toxicity, and modifiability. The tumor microenvironment (TME) plays a crucial role in the development of HNSCC and can be targeted using nanotherapy to regulate angiogenesis, immune response, tumor metastasis, and other factors, thereby alleviating symptoms and improving therapeutic efficacy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell Biology
Peng Shao, Wei-Wei Hu, Xin-lian Shi, Ming-yang Shu, Dong-Ya Li, Tingting Zhou, Qi-Tao Zhao
Summary: NK cells play a role in head and neck squamous cell carcinoma (HNSCC), and the gene EZR is identified as being associated with prognosis and its impact on the immune microenvironment and drug sensitivity in HNSCC.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2023)
Article
Oncology
Shoujing Zhang, Wenyi Zhang, Jian Zhang
Summary: Immunotherapy targeting the tumor microenvironment is effective in treating HNSCC, but there has been limited research on the relationship between HNSCC microenvironment and prognostic outcome. This study evaluated tumor immune cell infiltration and developed an immune-related prognostic signature and prediction model, providing promising clues for improving HNSCC survival prediction, individualized treatment strategies, and discovering immunotherapy biomarkers.
Article
Oncology
Katie E. Blise, Shamilene Sivagnanam, Grace L. Banik, Lisa M. Coussens, Jeremy Goecks
Summary: There is increasing evidence that the spatial organization of cells within the tumor-immune microenvironment influences survival and response to therapy in various cancer types. This study investigated the spatial proteomics of HPV-negative head and neck squamous cell carcinoma tumors and found that the spatial compartmentalization of neoplastic tumor-immune cells is associated with longer progression free survival. This suggests that spatial organization may have prognostic value in multiple cancer types.
NPJ PRECISION ONCOLOGY
(2022)
Article
Medical Laboratory Technology
Yiming Shen, Zhengyu Wei, Chongchang Zhou, Jiangping Song, Jianing Wang, Jiada Wang, Linrong Wu, Shenzhe Fang, Zhisen Shen
Summary: Expressions of Arylsulfatase I (ARSI) in head and neck squamous cell carcinoma (HNSC) are correlated with prognosis, immune cell status, and drug sensitivity, and may be involved in tumor cell escape and inflammatory responses.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2022)
Article
Oncology
David W. Andrews, Kevin D. Judy, Charles B. Scott, Samantha Garcia, Larry A. Harshyne, Lawrence Kenyon, Kiran Talekar, Adam Flanders, Kofi-Buaku Atsina, Lyndon Kim, Nina Martinez, Wenyin Shi, Maria Werner-Wasik, Haisong Liu, Mikhail Prosniak, Mark Curtis, Rhonda Kean, Donald Y. Ye, Emily Bongiorno, Sami Sauma, Mark A. Exley, Kara Pigott, D. Craig Hooper
Summary: IGV-001 demonstrated good tolerability in newly diagnosed glioblastoma patients, with a significantly improved median progression-free survival (PFS) compared to standard of care (SOC). In patients eligible for Stupp criteria, IGV-001 showed positive outcomes in terms of PFS and overall survival, suggesting a potential immune-mediated mechanism.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Dante J. Merlino, Jennifer M. Johnson, Madalina Tuluc, Stacey Gargano, Robert Stapp, Larry Harshyne, Benjamin E. Leiby, Adam Flanders, Ralph Zinner, Rita Axelrod, Joseph Curry, David M. Cognetti, Kyle Mannion, Young J. Kim, Ulrich Rodeck, Athanassios Argiris, Adam J. Luginbuhl
FRONTIERS IN ONCOLOGY
(2020)
Article
Immunology
Michael Prosniak, Larry A. Harshyne, Jonathan Gorky, Mark T. Curtis, Lawrence C. Kenyon, James S. Schwaber, Aurore Lebrun, Rhonda B. Kean, David W. Andrews, D. Craig Hooper
Summary: Patients with grade III anaplastic astrocytomas (AA) can be categorized into distinct immune bias profiles based on the presence or absence of mutations in isocitrate dehydrogenase (IDH). Two different immune biases were identified in patients with different IDH mutational status, with type 2 bias more common in IDH wild-type AA and type 1 bias more common in patients with IDH1R132H mutation. Additionally, the patient's immune profile was found to be more closely associated with tumor vascular enhancement on imaging rather than IDH mutational status.
JOURNAL OF IMMUNOLOGY
(2021)
Meeting Abstract
Oncology
J. M. Curry, A. Alnemri, S. Sussman, L. Harshyne, A. Linnenbach, R. Stapp, A. South, U. Nwagu, B. Swendseid, M. Tuluc, S. Gargano, D. Cognetti, V. Bar-Ad, A. Luginbuhl, R. Axelrod, D. Whitaker-Menezes, M. G. Mahoney, A. Argiris, U. Martinez-Outschoorn, J. M. Johnson
ANNALS OF ONCOLOGY
(2021)
Meeting Abstract
Oncology
Joseph M. Curry, Angela Alnemri, Brian Swendseid, Uche Nwagu, David M. Cognetti, Voichita C. Bar-Ad, Adam Luginbuhl, Rita Susan Axelrod, Diana Whitaker-Menezes, Larry Harshyne, Andrew South, My G. Mahoney, Alban Linnenbach, Athanassios Argiris, Ulrich Rodek, Ubaldo Martinez-Outschoorn, Jennifer Maria Johnson
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Adam J. Luginbuhl, Jennifer M. Johnson, Larry A. Harshyne, Alban J. Linnenbach, Sanket K. Shukla, Angela Alnemri, Gaurav Kumar, David M. Cognetti, Joseph M. Curry, Nikita Kotlov, Zoya Antysheva, Sandrine Degryse, Kyle Mannion, Michael K. Gibson, James Netterville, Brandee Brown, Rita Axelrod, Ralph Zinner, Madalina Tuluc, Stacey Gargano, Benjamin E. Leiby, Ayako Shimada, My G. Mahoney, Ubaldo Martinez-Outschoorn, Ulrich Rodeck, Young J. Kim, Andrew P. South, Athanassios Argiris
Summary: The addition of phosphodiesterase-5 inhibitor tadalafil to the PD-1 inhibitor nivolumab is safe and enhances immune-mediated antitumor responses in previously untreated squamous cell carcinoma of the head and neck. The combination therapy results in a pathologic treatment response of at least 20% in over 50% of the patients after 4 weeks of treatment. Pretreatment specimens show HPV status-dependent signatures that predict response to immunotherapy, while posttreatment specimens demonstrate an enhanced immune microenvironment with the addition of tadalafil.
CLINICAL CANCER RESEARCH
(2022)
Meeting Abstract
Oncology
I. Vathiotis, J. M. Johnson, L. Harshyne, A. Luginbuhl, J. M. Curry, D. Cognetti, R. Axelrod, V. Bar-Ad, A. Argiris
ANNALS OF ONCOLOGY
(2022)
Meeting Abstract
Oncology
J. Riordan, A. Linnenbach, A. Alnemri, R. Philips, S. Awosanya, S. Sussman, A. Luginbuhl, D. Cognetti, L. Harshyne, M. Mahoney, A. South, D. Whitaker-Menezes, M. Tuluc, A. Argiris, U. Martinez-Outschoorn, J. M. Johnson, J. M. Curry
ANNALS OF ONCOLOGY
(2022)
Meeting Abstract
Oncology
L. Harshyne, A. Linnenbach, M. Mahoney, A. South, U. Martinez-Outschoorn, J. M. Curry, D. Cognetti, J. M. Johnson, M. Tuluc, A. Argiris, A. Luginbuhl
ANNALS OF ONCOLOGY
(2022)
Meeting Abstract
Oncology
A. Luginbuhl, E. Scott, L. Harshyne, E. Flerova, M. Tuluc, S. Gargano, J. M. Curry, D. Cognetti, A. Argiris, J. M. Johnson
ANNALS OF ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Joseph Curry, Angela Alnemri, Ramez Philips, Michele Fiorella, Sarah Sussman, Robert Stapp, Charalambos Solomides, Larry Harshyne, Andrew South, Adam Luginbuhl, Madalina Tuluc, Ubaldo Martinez-Outschoorn, Athanassios Argiris, Alban Linnenbach, Jennifer Johnson
Summary: This study analyzed the cellular density and intercellular distances of CD8+ and FoxP3+ T-cells in head and neck squamous cell carcinoma samples. The results showed that the distribution of CD8+ and FoxP3+ cells was associated with treatment outcomes and pathological treatment response. Increased CD8+-FoxP3+ intercellular distances were closely related to pathological treatment response.
Article
Immunology
Christopher Herbst, Larry A. Harshyne, Botond Z. Igyarto
Summary: Dendritic cells can actively acquire antigens from neighboring cells and assess the health of the donor cells through cell-cell interactions.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Brianna L. L. Hill, Alyssa N. N. Calder, Joseph P. P. Flemming, Yiyang Guo, Sydney L. L. Gilmore, Melissa A. A. Trofa, Sean K. K. Daniels, Torbjoern N. N. Nielsen, Laura K. K. Gleason, Zoya Antysheva, Ksenia Demina, Nikita Kotlov, Christopher J. H. Davitt, David M. M. Cognetti, George C. C. Prendergast, Adam E. E. Snook, Jennifer M. M. Johnson, Gaurav Kumar, Alban J. J. Linnenbach, Ubaldo Martinez-Outschoorn, Andrew P. P. South, Joseph M. M. Curry, Larry A. A. Harshyne, Adam J. J. Luginbuhl, My G. Mahoney
Summary: Therapy using anti-PD-1 immune checkpoint inhibitors has revolutionized cancer treatment, but only a fraction of patients respond. The study identified Dsg2, miR-146a, and IL-8 as potential biomarkers for ICI response in HPVpos HNSCC patients, suggesting that targeting the Dsg2/miR-146a/IL-8 signaling axis could improve ICI responsiveness.
MOLECULAR CARCINOGENESIS
(2023)
Meeting Abstract
Oncology
Adam Luginbuhl, Jennifer Maria Johnson, Elizabeth R. Scott, Larry Harshyne, Elizaveta Flerova Flerova, Madalina Tuluc, Stacey Gargano, Benjamin Leiby, Matthew O. Old, Nolan Seim, Joseph M. Curry, David M. Cognetti, Athanassios Argiris
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Nikita Kotlov, Zoya Antysheva, Dina Antonova, Naira Samarina, Sandrine Degryse, Alban Linnenbach, Sanket Shukla, Larry Harshyne, Andrew P. South, Jennifer M. Johnson, Young Kim, Alexander Bagaev, Nathan H. Fowler, Adam Luginbuhl